Director/PDMR Shareholding
RNS Announcements
2024
Holding(s) in Company
27 September 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that it has received a TR-1 Form, which is reproduced without amendment below.
The TR1 Form reflects transfers made from the holding of Holdingselskabet af 29. Juni 2010 Aps, the family office vehicle of Frederik Bruhn-Petersen, to members of Mr Bruhn-Petersen's family.
For further information, please contact:
ProBiotix Health plc | |
Steen Andersen, Chief Executive Officer |
|
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | Tel: 020 7469 0930 |
Mark Anwyl
| |
Walbrook PR Ltd Anna Dunphy | Mob: 07876 741 001 |
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | PROBIOTIX HEALTH PLC | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify): | ||||||
3. Details of person subject to the notification obligation | ||||||
Name | Holdingselskabet af 29. juni 2010 ApS | |||||
City and country of registered office (if applicable) | COPENHAGEN, DENMARK | |||||
4. Full name of shareholder(s) (if different from 3.) | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reached: | 25/09/2024 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 26/09/2024 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
Resulting situation on the date on which threshold was crossed or reached | 20.97% | 20.97% | 158,166,666 | |||
Position of previous notification (if applicable) | 23.08% | 23.08% | ||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rights | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB00BLNBFR86 | 33,160,000 | 20.97% | |||||||
SUBTOTAL 8. A | |||||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of Financial instrument | Expiration | Exercise/ Period | Physical or cash settlement | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | ||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | ||||
Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional information | ||||
Place of completion | Copenhagen, Denmark |
Date of completion | 26/09/2024 |
2023
Holding(s) in Company
27 September 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that it has received a TR-1 Form, which is reproduced without amendment below.
The TR1 Form reflects transfers made from the holding of Holdingselskabet af 29. Juni 2010 Aps, the family office vehicle of Frederik Bruhn-Petersen, to members of Mr Bruhn-Petersen's family.
For further information, please contact:
ProBiotix Health plc | |
Steen Andersen, Chief Executive Officer |
|
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | Tel: 020 7469 0930 |
Mark Anwyl
| |
Walbrook PR Ltd Anna Dunphy | Mob: 07876 741 001 |
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | PROBIOTIX HEALTH PLC | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify): | ||||||
3. Details of person subject to the notification obligation | ||||||
Name | Holdingselskabet af 29. juni 2010 ApS | |||||
City and country of registered office (if applicable) | COPENHAGEN, DENMARK | |||||
4. Full name of shareholder(s) (if different from 3.) | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reached: | 25/09/2024 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 26/09/2024 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
Resulting situation on the date on which threshold was crossed or reached | 20.97% | 20.97% | 158,166,666 | |||
Position of previous notification (if applicable) | 23.08% | 23.08% | ||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rights | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB00BLNBFR86 | 33,160,000 | 20.97% | |||||||
SUBTOTAL 8. A | |||||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of Financial instrument | Expiration | Exercise/ Period | Physical or cash settlement | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | ||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | ||||
Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional information | ||||
Place of completion | Copenhagen, Denmark |
Date of completion | 26/09/2024 |
2022
Holding(s) in Company
27 September 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that it has received a TR-1 Form, which is reproduced without amendment below.
The TR1 Form reflects transfers made from the holding of Holdingselskabet af 29. Juni 2010 Aps, the family office vehicle of Frederik Bruhn-Petersen, to members of Mr Bruhn-Petersen's family.
For further information, please contact:
ProBiotix Health plc | |
Steen Andersen, Chief Executive Officer |
|
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | Tel: 020 7469 0930 |
Mark Anwyl
| |
Walbrook PR Ltd Anna Dunphy | Mob: 07876 741 001 |
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | PROBIOTIX HEALTH PLC | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify): | ||||||
3. Details of person subject to the notification obligation | ||||||
Name | Holdingselskabet af 29. juni 2010 ApS | |||||
City and country of registered office (if applicable) | COPENHAGEN, DENMARK | |||||
4. Full name of shareholder(s) (if different from 3.) | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reached: | 25/09/2024 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 26/09/2024 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
Resulting situation on the date on which threshold was crossed or reached | 20.97% | 20.97% | 158,166,666 | |||
Position of previous notification (if applicable) | 23.08% | 23.08% | ||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rights | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB00BLNBFR86 | 33,160,000 | 20.97% | |||||||
SUBTOTAL 8. A | |||||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of Financial instrument | Expiration | Exercise/ Period | Physical or cash settlement | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | ||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | ||||
Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional information | ||||
Place of completion | Copenhagen, Denmark |
Date of completion | 26/09/2024 |
Latest RNS News
Latest Interview
Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube